William L Sellers

US Patent:

6949342, Sep 27, 2005

Filed:

Dec 19, 2002

Appl. No.:

10/325457

Inventors:

Todd R. Golub - Newton MA, US
Phillip G. Febbo - Jamaica Plain MA, US
Kenneth N. Ross - Boston MA, US
William R. Sellers - Chestnut Hill MA, US

Assignee:

Whitehead Institute for Biomedical Research - Cambridge MA
Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q001/68
G01N033/53

US Classification:

435 6, 435 71

Abstract:

Methods identifying prostate cancer, methods for prognosing and diagnosing prostate cancer, methods for identifying a compound that modulates prostate cancer development, methods for determining the efficacy of a prostate cancer therapy, and oligonucleotide microarrays containing probes for genes involved in prostate cancer development are described.

US Patent:

7294468, Nov 13, 2007

Filed:

Dec 5, 2005

Appl. No.:

11/294621

Inventors:

Daphne Winifred Bell - Arlington MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnson - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US

Assignee:

The General Hospital Corporation - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q 1/68

US Classification:

435 6, 424 91, 435 912

Abstract:

The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

US Patent:

7501248, Mar 10, 2009

Filed:

Sep 26, 2005

Appl. No.:

11/236702

Inventors:

Todd R. Golub - Newton MA, US
Phillip G. Febbo - Jamaica Plain MA, US
Kenneth N. Ross - Boston MA, US
William R. Sellers - Chestnut Hill MA, US

Assignee:

Whitehead Institute for Biomedical Research - Cambridge MA
Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

Methods identifying prostate cancer, methods for prognosing and diagnosing prostate cancer, methods for identifying a compound that modulates prostate cancer development, methods for determining the efficacy of a prostate cancer therapy, and oligonucleotide microarrays containing probes for genes involved in prostate cancer development are described.

US Patent:

7964349, Jun 21, 2011

Filed:

Aug 20, 2007

Appl. No.:

11/894159

Inventors:

Daphne Winifred Bell - Arlington MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US

Assignee:

The General Hospital Corporation - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

US Patent:

7981609, Jul 19, 2011

Filed:

Jun 8, 2007

Appl. No.:

11/811149

Inventors:

Mark A. Rubin - Cambridge MA, US
Francesca Demichelis - Cambridge MA, US
Levi A. Garraway - Newton MA, US
William R. Sellers - Brookline MA, US

Assignee:

The Brigham and Women's Hospital, Inc. - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

Described are methods for identifying single nucleotide polymorphism (SNPs) that are useful for analyzing genetic samples, and for using said SNPs to determine genetic identity of samples.

US Patent:

8105769, Jan 31, 2012

Filed:

Aug 20, 2007

Appl. No.:

11/894135

Inventors:

Daphne Winifred Bell - Arlington MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US

Assignee:

The General Hospital Corporation - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

US Patent:

8465916, Jun 18, 2013

Filed:

Aug 20, 2007

Appl. No.:

11/894160

Inventors:

Daphne Winifred Bell - Arlington MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US

Assignee:

The General Hospital Corporation - Boston MA
Dana Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q 1/68

US Classification:

435 61

Abstract:

The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

US Patent:

20060008838, Jan 12, 2006

Filed:

Sep 6, 2005

Appl. No.:

11/221302

Inventors:

Todd Golub - Newton MA, US
Phillip Febbo - Jamaica Plain MA, US
Kenneth Ross - Boston MA, US
William Sellers - Chestnut Hill MA, US

Assignee:

Whitehead Institute for Biomedical Research - Cambridge MA
Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q 1/68

US Classification:

435006000

Abstract:

Methods identifying prostate cancer, methods for prognosing and diagnosing prostate cancer, methods for identifying a compound that modulates prostate cancer development, methods for determining the efficacy of a prostate cancer therapy, and oligonucleotide microarrays containing probes for genes involved in prostate cancer development are described.